Author: Editor

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. Commonly asked questions are answered and he provides insight on standard treatment. _________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug –…

Read More

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. __________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug – approved by the FDA for lung cancer only – showed promising results…

Read More

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI explains some common questions regarding PTEN patients. _________ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are…

Read More

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI clarifies genetic autism in PTEN patients. _______ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are associated…

Read More

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Read More

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma

Read More

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world evidence for oncologists.

Read More

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue and is currently available online. This study examined the activity of…

Read More

National Comprehensive Cancer Network to address HPV-related cancer prevention and treatment with World Cancer Day fundraiser and at upcoming NCCN 2020 Annual Conference. Learn more at NCCN.org/wcd and join the conversation online with hashtags #WorldCancerDay, #IAmAndIWill, and #NCCNGlobal.  — February 4, 2020, marks the 20th annual World Cancer Day. On this day, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers—is commemorating its 25th anniversary year by looking back at the tremendous progress made against cancer over the past quarter-century and looking forward to further define and advance high-quality, high-value, patient-centered cancer care globally. Earlier this year, the American Cancer Society (ACS) announced that the cancer death…

Read More

United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC). The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone. The safety profile of dinutuximab in DISTINCT was consistent with prior studies and the current Unituxin product label. Full data from the DISTINCT study will be made available through scientific disclosure at upcoming conferences and in peer-reviewed publications.   “We thank the principal investigators, patients and…

Read More

Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients and more common questions about NMP1 AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31,…

Read More

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its open label, single arm US Phase 1 trial met its primary objective of demonstrating the safety of Liposomal Annamycin (“Annamycin”) in treating relapsed or refractory acute myeloid leukemia (“AML”). The Company also announced an update on interim enrollment, safety and efficacy data in its parallel Phase 1 trial in Europe, which continues with dose escalation, thus far without safety concerns. Safety of Annamycin in AML Patients The US Phase 1 trial met its…

Read More

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the treatment of NPM1 in AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue…

Read More